Purpose To examine the impact of systematic medication reconciliations upon hospital admission and of a medication review while in hospital on the number of inappropriate medications and unscheduled drug-related hospital revisits in elderly patients.
Methods This was a prospective, controlled study in 210 patients, aged 65 years or older, who were admitted to one of three internal medicine wards at a University Hospital in Sweden. Intervention patients received the complete Lund Integrated Medicines Management model (medication reconciliation upon admission and discharge, and medication review and monitoring) provided by a multi-professional team, including a clinical pharmacist. Control patients received standard care and medication reconciliation upon discharge. Blinded reviewers evaluated the appropriateness of the prescribing (using the Medication Appropriateness Index) on admission and discharge, and assessed the probability that a drug-related problem was the reason for any patient readmitted to hospital or visiting the emergency department within 3 months of discharge (using World Health Organisation causality criteria). Results There was a greater decrease in the number of inappropriate drugs in the intervention group than in the control group for both the intention-to-treat population {51% [95% confidence interval (CI) 43-58%] vs. 39% (95% CI 30-48%); p=0.0446} and the per-protocol population [60% (95% CI 51-67%) vs. 44% (95% CI 34-52%); p=0.0106)]. There were six revisits to hospital in the intervention group which were judged as 'possibly, probably or certainly drugrelated', compared with 12 in the control group (p=0.0469). Conclusions In this study, medication reconciliation and review provided by a clinical pharmacist in a multiprofessional team significantly reduced the number of inappropriate drugs and unscheduled drug-related hospital revisits among elderly patients.
Keywords Clinical pharmacy services . Medication Appropriateness Index . Medication review . Medication reconciliation . Drug-related problems . Inpatients Introduction Drug treatment is an important component of medical care for the elderly and has the potential to decrease morbidity and mortality and to increase the quality of life. However, problems associated with drug treatment are frequent among elderly hospitalised patients [1, 2] and, for some patients, it can be a drug-related problem that causes the hospital admission [3] [4] [5] . Many drug-related problems can be solved or prevented; it has been estimated that more than half of the drug-related admissions to hospital are preventable [6] . A number of different underlying causes of drugrelated hospital admissions have been identified; for example, clinically inappropriate drug regimens, lack of sufficient monitoring and follow-up, insufficient quality of information transfer between levels of care and poor adherence to drug treatment among patients. Given the complexity of the process leading to a drug-related hospital admission [6, 7] , it is likely that interventions for solving and preventing drug-related admissions and other negative consequences from drug therapy need to be multi-faceted.
An integrated medicines management approach, involving input by clinical pharmacists at admission, during the hospital stay and at discharge has been shown to be effective in reducing health care utilisation [8] and improving medication appropriateness [9, 10] . We have developed the Lund Integrated Medicines Management (LIMM) model, which describes a systematic approach to individualising and optimising drug treatment in elderly inpatients. A more detailed description of the LIMM model is presented in Table 1 . Medicine management is defined as a concept that seeks to maximise health through the optimum use of medical drugs [11] , and the term 'integrated' indicates that different levels of care are involved including, for example, hospital and primary care. The model covers several aspects of the use of medications, from appropriate prescribing to the ways in which the drugs are taken or not taken by the patients [11] . Appropriate prescribing is associated with a range of factors, with three of the most important being the patient's needs, the pharmaceutical/pharmacological qualities of the drug and the well-being of the general population [12] . The Medication Appropriateness Index (MAI) is a validated instrument for measuring the pharmacological and economic aspects of prescribing appropriateness, and the criteria used in the MAI can be described as a combination of implicit (judgment-based) and explicit (criterion-based) criteria [13] . Results from an earlier study of the LIMM model showed positive effects on the appropriateness of drug therapy according to the MAI [10] , but they also suggested the need for a larger controlled study to confirm the results.
The main objective of this study was to examine the impact of medication reconciliations upon hospital admission and inpatient medication review, according to the LIMM model, on the number of inappropriate medications taken by elderly patients at discharge from hospital. The secondary objective was to examine the effect of LIMMbased patient care on the number of unscheduled drugrelated hospital readmissions and emergency department visits within 3 months of hospital discharge.
Methods

Patients and setting
In this prospective controlled study, we compared patients receiving LIMM-based medication reconciliation upon admission and discharge and medication review and monitoring during the hospital stay (the intervention group) with patients receiving standard care and LIMM-based medication reconciliation at discharge (the control group).
The intervention was implemented in three internal medicine wards (A, B and C) at Skåne University Hospital in Lund, Sweden, between January 2007 and March 2008 (Fig. 1) . The patients in all three wards received standard care and LIMM-based discharge medication reconciliation until implementation of the complete LIMM model, which was started at different times in the respective wards (see Fig. 1 ). All patients in wards A, B and C received the intervention after it had been implemented, but the patients evaluated retrospectively for eligibility for inclusion in the study included only those who were staying in the study wards on November 1, 2006 (before the intervention), and March 1, 2007, November 1, 2007 and April 1, 2008 (about 1 month after implementation of the intervention in wards A, B and C, respectively). Patients were included if they: (1) were aged 65 years or older and (2) had been prescribed at least one drug for regular use. Patients were excluded if they had been staying in the study wards during one of the previous inclusion dates. The regional Ethical Review Board did not consider an ethical approval to be necessary and raised no objections to the study.
Multi-professional team intervention according to the LIMM model
During the intervention periods, clinical pharmacists conducted the medication reconciliation upon admission of the patient to the ward and reviewed and monitored medication during the hospital stay according to the LIMM model. The admission medication reconciliation was performed on weekdays, shortly after the patient had been admitted, using the LIMM Medication Interview Questionnaire parts 1-3 [14] ( Table 1) . Firstly, the most accurate patient medication list was identified (part 1 of the medication interview question-naire). The current medication list in the electronic medical record was compared with lists from other sources, including that of the patients and their close relations, drug lists from primary or community care and the national computerised pharmacy dispensing register. On the basis of identified discrepancies, the pharmacist suggested changes to the current drug list in a face-to-face discussion with a ward physician. Secondly, patients who took responsibility for their own drug treatment at home were interviewed about other aspects of their drug use in part 2 of the interview (Table 1) . Finally, if the patient was capable and willing to participate, in-depth questions concerning adherence to the drug regimen [15] and personal attitudes regarding medications [16] were added to the interview (part 3). Any problems concerning the patient's drug use that emerged during the interview were addressed by the pharmacist by means of counselling and/or written information, including ward-specific drug information leaflets. On weekdays, before morning rounds, the pharmacists identified drug-related problems by conducting structured medication review that addressed the following categories of risk: drugs that required therapeutic drug monitoring, less appropriate drug therapy, interchangeable drugs (according to a regional interchangeable list), problems with drug handling (e.g. swallowing, crushing, inhalation), drug interactions, type of drug or drug dose not adjusted according to liver/renal function, indication for drug treatment not known, natural remedy drugs, untreated indication and drugs causing adverse drug reactions. Information sources included the patient's medication list, medical record notes, laboratory values and other relevant data. During ward rounds, the drug-related problems which the pharmacist considered to be the most relevant were discussed within the multi-professional team (physicians, nurses, carers and paramedics). Patients were followed up at least twice a week to enable identification of new drugrelated problems and to monitor previously identified problems. All data were documented on the LIMM Medication Review Form (Table 1) .
Clinical pharmacists did not work in the wards during the standard care control periods, and no formal medication reviews were undertaken. In some cases, informal medication reconciliation at admission was undertaken, but there were no tools or instructions for this.
During both the control and intervention periods, patients and primary or community care personnel received a Discharge Information Form, which included a Medication Report describing changes in drug treatment during the hospital stay and a Medication List (Table 1) . Hence, this LIMM-based discharge medication reconciliation was not part of the evaluation; the benefit of this procedure has already been demonstrated [17, 18] .
Data collection and outcome measures
The primary outcome measure was the change in the number of drugs with at least one inappropriate score (C; see following section) between admission and discharge, according to the MAI (see following section). Secondary outcome measures included the number of patients revisiting the hospital because of a drug-related complaint within 3 months of discharge and MAI scores for each patient and drug at discharge.
Medication Appropriateness Index (MAI)
The ten items that comprise the MAI are indication, drug effectiveness, correct dosage, correct directions, practical directions, drug-drug interactions, drug-disease interactions, drug duplication, duration of treatment and expense. Each drug was rated as appropriate (A), marginally appropriate (B) or inappropriate (C) for each of the ten items [13] . In the analysis, ratings for individual items were dichotomised as appropriate (A or B) versus inappropriate (C). A drug was categorised as inappropriate if it received a 'C' assessment for at least one of the ten MAI items. According to a weighting scheme, a summed MAI score of between 0 and 18 can be produced for each medication [19] , and a patient's personal MAI score can be calculated by summing the scores of all medications for each patient. The literature indicates that the overall inter-rater reliability of this index is moderate to very good and that the overall intra-rater reliability is good to very good [13, [19] [20] [21] [22] . The content validity has also been shown to be good [18] . In some cases, however, the reliability of a few specific individual MAI items has been rated fair to poor [20] . Clinical judgment is needed to assess some items, although the rating process has been standardised by including explicit instructions on how to interpret each of the ten items [13] .
The MAI assessments were made retrospectively by a research assistant (junior clinical pharmacist, MSc Pharmacy) who was not involved in the care of the patients and who had been trained in the use of the MAI by an experienced clinical pharmacist and researcher (Fig. 2) . The MAI was applied to drugs taken regularly; topical drugs, laxatives and drugs taken as needed were excluded. Patient data used in the MAI assessment of drugs at admission included the drug list at admission, laboratory and diagnostic test results, and medical record notes on the patient made at admission and on the first day in hospital. The research assistant was blinded to group allocation.
The MAI assessments for drugs at discharge were performed in two steps for the intervention group (Fig. 2 ) and one step for the control group. In step 1, the control and intervention patients were assessed using the drug list at discharge, the medical record notes during the hospital stay, the laboratory and diagnostic test results and the discharge summary. The research assistant performing the assessment was blinded with respect to group allocation. In step 2, the intervention patients were reassessed; patient information documented in the pharmacist's Medication Review Form was made available to the reviewer and the MAI scores for drugs receiving an inappropriate rating in step 1 were reevaluated based on this information. As medication review forms were only produced for intervention patients, the research assistant could not remain blinded to group allocation at this step. The step 2 assessment was performed because some information in the Medication Review Forms had not been documented in the patient's medical record by the physicians, which could potentially have changed the MAI scores. To avoid bias, we only used those results from the first step of the discharge MAI assessment (the blinded evaluation) in the main analysis.
Drug-related hospital revisits
Data collected from the electronic medical records of patients who had an unscheduled readmission or visit to the emergency department of Skåne University Hospital, Lund, within 3 months of discharge were used as the basis of the evaluation of the reason for the revisit to hospital. If a patient had several unscheduled revisits to hospital within three months, only data from the first contact were used.
In the reviewing process, we combined clinical judgment with the use of predetermined triggers, namely combinations of drugs and symptoms or certain 'high-alert' medications [3-5, 23, 24] . As shown in Fig. 2 , the initial review, which was performed by a research assistant supported by an experienced clinical pharmacist, was followed by a final review by a multi-professional expert group of senior researchers and clinicians (one clinical pharmacist, one clinical pharmacologist, one consultant in internal medicine/geriatrics and one general practitioner). The initial reviewers were as inclusive as possible when choosing cases for further review; cases were classified as 'potentially drug-related' and reviewed by the expert group if there was even the smallest suspicion of a drug-related revisit.
The expert group classified the type of drug-related problem as adverse drug reaction, therapeutic failure (including non-compliance, dose reduction/discontinuation, dose too low, drug interaction, inadequate therapeutic drug monitoring) or untreated indication. The cases were further classified by using the World Health Organisation (WHO) criteria for causality [25] ; the causal relationship between the drug treatment and a symptom or diagnosis present at the hospital revisit was classified as 'certain', 'probable', 'possible' or 'unlikely'. In addition, the contribution of the drug-related problem to the hospital revisit was assessed and classified as 'dominant', 'partly contributing', 'less important' or 'not contributing' [26] . Drug-related problems associated with medications that had been newly initiated in the outpatient setting after discharge from hospital were excluded from the assessment, as we only wanted to evaluate the treatment that was a result of hospital care during the study. All reviewers in the initial and final reviews were blinded to group allocation. In the statistical analysis, the hospital revisits were classified as drug-related only when 'possible, 'probable' or 'certain' drug-related cases were also classified as the 'dominant cause' for or 'partly contributing' to the revisit.
Interventions during hospital stay
Admission Medication Reconciliation
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Statistics
To assess the comparability of study groups at study inclusion, we used Student's t test, the Mann-Whitney test and Fisher's exact test when appropriate. The difference in the number of drugs with inappropriate ratings was analysed by Poisson regression, with an offset equal to the natural logarithm of the number of inappropriate drugs at admission. Because the natural logarithm for zero does not exist, all zeros in the offset variable were set to 0.3. Our choice was based on comparisons of a number of values between 0.01 and 0.5, which showed that 0.3 gave the best fit of the model to the data. We also judged it to be an appropriate distance from 1. The Mann-Whitney test was used when comparing MAI scores between the intervention and control groups. For the MAI calculations, bootstrap 95% confidence intervals (CIs) for the means were obtained by using the re-sampling technique [27] . The main analyses of the MAI results were performed according to the intention-to-treat (ITT) principle, using the 'baseline observation carried forward' for missing observations. A perprotocol (PP) analysis of patients who had received the complete intervention (both medication reconciliation and review) and who did not die in hospital was also carried out. The chi-squared test for trend was used to analyse drug-related revisits to hospital. The significance level in all analyses was set to 0.05. The R language and environment for statistical computing program (www.r-project.org) was used for the statistical analysis. The power calculation performed for the primary objective was based on the results of a previous study of the LIMM model in 53 patients, which showed that the number of drugs with at least one inappropriate rating decreased by 33% in the intervention group and 7% in the control group [10] . We believed that it would be valuable to detect an even smaller difference between the groups and wanted to account for loss to follow-up; after performing a number of simulations, we therefore decided to include at least 100 patients in each group.
Results
Of the 232 patients eligible for inclusion, 210 were enrolled in the study (Fig. 3) . Fifteen patients in the intervention group did not receive the complete intervention due to a short length of stay in hospital, the absence of a clinical pharmacist during the weekends or closed wards due to an infection outbreak among the patients. In addition, 12 intervention patients (including 2 who did not receive the complete intervention) and nine control patients died during the initial hospital stay. Eighty-four intervention patients and 92 control patients were therefore included in the perprotocol analysis. Demographic data at admission to hospital (baseline) are shown in Table 2 . Gender, age and number of drugs at admission were similar in both groups. The median (interquartile range) length of stay in hospital was 16 (9-28) days in the intervention group and 13 (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) days in the control group (p=0.0905). A current medication list was identified for all 97 patients who received medication reconciliation (part 1 of the LIMM Medication Interview Questionnaire). In addition, 23 of these 97 patients were interviewed regarding their knowledge of their medication and adherence to the drug regimen (part 2 of the questionnaire) and 17 of these 23 also completed the questionnaire on adherence to the drug regimen [15] and the other questionnaire on their personal attitudes regarding medications [16] (part 3).
Medication appropriateness index
Drugs with at least one inappropriate rating
There was a greater decrease in the number of drugs with at least one inappropriate rating in the intervention group than in the control group [51% (95% CI 43-58%) vs. 39% (95% CI 30-48%); p=0.0446] according to the intention-to-treat analysis of the MAI assessment, step 1. At discharge, 18.4% of the drugs for the intervention patients and 21.9% of the drugs for controls were rated as inappropriate.
In the per-protocol analysis, the number of drugs with at least one inappropriate rating decreased by 60% (95% CI 51-67%) in the intervention group, compared with 44% (95% CI 34-52 %) in the control group (p=0.0106). At discharge, 15.1% of the drugs for the intervention group and 20.2% of the drugs for the control group were rated as inappropriate. The mean number of drugs with at least one inappropriate rating per patient, at admission and discharge, is shown in Table 3 .
The mean number of inappropriate drugs changed between admission and discharge as a result of discontinuing inappropriate drugs, initiating inappropriate drugs, adjusting existing therapy to more appropriate therapy (for example, by changing the dose) or improving documentation (for example, stating the indication for a specific drug in the medical record). The number of inappropriate drugs that were discontinued, initiated or adjusted is shown in Table 4 .
In the MAI assessment, step 2 (performed in the intervention group at discharge), 93 patients (all patients who received medication review and did not die during the hospital stay) were assessed. The MAI rating was changed from a C to an A or B for 27 drugs in 19 patients. The average decrease per patient between step 1 and 2 in the number of drugs with at least one C rating was 0.44 (95% CI 0.26-0.63). Table 5 shows that the MAI item 'expense' received the greatest number of inappropriate ratings in both control and intervention patients, followed by 'indication' and 'duration'. When the indication was rated as inappropriate, both expense and duration also received an inappropriate rating, in line with the MAI instructions. In the intervention group, there were improvements in all MAI criteria except 'effectiveness' and 'correct directions' (Table 5 ). In the control group, improvement was obtained for six of the ten criteria. Fig. 3 Flow of patients through the study. a Some patients did not receive the full intervention because of their short length of stay in hospital, death during hospital stay, absence of clinical pharmacist during the weekends, or closed wards due to infection outbreak among the patients. Patients lost to follow-up died during the hospital stay. The 12 patients in the intervention group who died in the hospital include the two patients who had also not received the complete intervention.
MAI items
c One patient from each group was excluded from the analysis due to insufficient medical record data
MAI scores
The average MAI scores per patient and per drug both at admission and discharge are shown in Table 3 . No significant differences between the control and intervention groups at discharge were found in the patient MAI score (ITT p=0.553; PP p = 0.421), or the MAI score per drug (ITT p = 0.543; PP p = 0.329).
Drug-related revisits to the hospital Within 3 months of discharge, 71 patients were readmitted (unscheduled admissions) to hospital and 15 visited the emergency department. Two patients (one intervention and one control) were excluded from the analysis due to insufficient medical record data. There were six revisits to hospital with a causality assessment of 'possible', 'probable' or 'certain' in the intervention group compared with 12 in the control group (p = 0.0469) ( Table 6 ). Among the drug-related cases, three patients visited the emergency department without being admitted to hospital and 15 patients were admitted to a hospital ward.
In 5.6% of intervention patients (6/108) and 12.0% of control patients (12/100), the revisit to hospital was at least possibly drug related (p = 0.138, Fisher's exact test). The absolute risk reduction for possibly drug-related revisits Table 3 Number of drugs with at least one inappropriate rating per patient according to the Medication Appropriateness Index (MAI), MAI score per patient and MAI score per drug at admission and discharge Intervention group (ITT, n=109; PP, n=84)
Control group (ITT, n=101; PP, n=92) Admission Discharge Admission Discharge
Step 1 a
Step 2
Number of drugs with at least one inappropriate rating Control group (admission, n=783 drugs; discharge, n=785)
Step 1
Step 2 (18) 22 (17) 28 (16) a Data are given as the number of inappropriate drugs at admission, with the percentage of the number of inappropriate drugs at admission in parenthesis b Data are given as the number of inappropriate drugs at discharge, with the percentage of the number of inappropriate drugs at discharge in parenthesis was 6.4% (95% CI −1.2% to 14.1%). The cases in which a drug-related problem was assessed as having a certain or probable relationship with the revisit to hospital are described in more detail in Table 7 .
Discussion
The results of this study showed that medication reviews and medication reconciliation on admission to hospital, carried out according to the LIMM model, were associated with a significant decrease in the number of inappropriate drugs taken by elderly hospitalised patients. In agreement with these results, a previous study showed a reduction in the number of drugs with at least one inappropriate rating after implementation of the LIMM model [10] . A number of earlier controlled studies on pharmaceutical care, integrated medicines management or other collaborative approaches in hospitalised patients have also shown improvements in the appropriateness of medications (decrease in the MAI scores) [9, 28, 29] .
In accordance with the previous study of the LIMM model [10] , we regarded 'the number of drugs with at least one inappropriate rating' to be the most suitable main outcome measure. This measure has also been used by other researchers [20, 28] . By using that measure we were able to avoid summing or subtracting scores, which is generally not recommended when dealing with ordered categorical data (i.e. the MAI scores A, B and C) [30] . Nonetheless, we have presented the MAI scores in this study in order to facilitate comparison with previous studies. In our study, the average patient MAI score in the intervention group at discharge was lower than that reported in most other studies (indicating more appropriate prescribing) [9, 10, 28, 29] . However, because the control group also had a very low patient MAI score, there were no Table 5 Percentage of drugs that were inappropriate for each MAI criterion at admission and discharge, according to the ITT analysis
MAI criteria
Intervention group (n = 109 patients) Control group (n = 101 patients) Admission (n=858 drugs) Discharge (n=868 drugs) Admission (n=783 drugs) Discharge (n=785 drugs)
Step 2 Data are given as the number of patients
Types of drug-related problems covered were: adverse drug reaction, therapeutic failure (including non-compliance, dose-reduction/ discontinuation, too low dose, drug interaction, inadequate therapeutic drug monitoring) and untreated indication a The World Health Organisation (WHO) criteria for causality comprised 'certain', 'probable', 'possible' or 'unlikely' b Hallas' criteria for contribution comprised: 'dominant', 'partly contributing', 'less important' and 'not contributing' apparent differences between the groups. In two previous interventions with a similar lack of improvement in the MAI scores [29, 31] , neither the intervention nor the control group improved.
In our main analysis we used the most conservative parameters possible, i.e. MAI scores from the blinded assessment (step 1), results from the intention-to-treat population, and 'baseline observation carried forward' for missing data. Despite this, the results still indicated a difference between the groups. When the per-protocol population and the nonblinded MAI assessment were analysed, the difference between the groups was larger, suggesting that the effect of the intervention may have been underestimated in the main analysis. The use of a blinded outcome assessment, as in our study and two other hospital-based MAI studies [29, 31] , strengthens the validity of the MAI ratings in comparison with those from other studies, which used reviewers who were not blind to group allocation [9, 10, 28] .
The clinical consequences of a reduction in the number of inappropriate drugs are difficult to estimate, since the evidence for an association between inappropriate prescribing and adverse patient outcomes is mixed and contradictory [32] . However, the results of the two studies that have been published on the predictive validity of the MAI indicate that this tool can reliably predict clinical patient outcomes [33, 34] . Lund et al. [33] showed that inappropriate prescribing, according to a modified MAI score, is associated with adverse drug events in older men, and Schmader et al. [34] demonstrated an association between worse MAI scores and poorer blood pressure control and the use of more health services.
Our study has a number of potential limitations. Firstly, the nonrandomised design could have introduced selection bias. Secondly, the study was undertaken solely in wards of internal medicine, limiting the generalisability of the results. With this in mind and to improve the generalisability, we developed a structured process for performing medication review and reconciliation and used structured forms (i.e. checklists and questionnaires). Finally, instead of performing two or more independent outcome assessments for each patient, a single rater or a single group of raters assessed the patient data. We decided to use only one rater for the MAI assessments, as previous studies of MAI have shown a good or very good agreement within raters [13, [19] [20] [21] [22] and the main purpose of this study was to quantify changes in MAI (where intra-rater agreement was more important [21] ). The group of reviewers evaluating the drug-related revisits to hospital was chosen to provide varied backgrounds and expert knowledge in order to minimise the risk of misclassifying the revisits. In addition, the reviewers used checklists for detecting drug-related problems and two different explicit criteria to classify the cases.
In a number of cases, the comprehensiveness and quality of the documentation in the medical records affected the appropriateness of the medication. Adding information from the medication review forms led to a change in the MAI rating from 'inappropriate' to 'appropriate' for 23% of the drugs at discharge. We have already demonstrated that communicating changes in the medication list, together with the reasons for these changes, to the patient and the next level of care decreases medication errors and the number of health care contacts [17, 18] . We suggest that there is potential to improve the quality of prescribing even more if a broader range of issues concerning medication appropriateness and drug-related problems is documented and communicated to the next level of care in a structured manner. We found a significant reduction in the number of unscheduled drug-related revisits within 3 months of discharge from hospital. Similarly, a recent randomised controlled study of a comparable intervention, also in Sweden, showed a reduction in all revisits to hospital as well as in drug-related readmissions [35] , and patients who received an integrated medicines management service in Northern Ireland benefitted from a decreased rate of readmission and an increased time to readmission [8] . It is probable that the effect of the entire LIMM intervention (at admission, during the hospital stay and at discharge) on a reduced need for medical care due to drug-related problems will approximate the sum of the effects of the discharge medication reconciliation (Discharge Information including a Medication Report and a Medication List) previously shown [17] and the admission medication reconciliation and review as demonstrated in this study.
Our findings confirm the effect on medication appropriateness previously shown by Bergkvist et al. [10] in a study of the entire LIMM model. In contrast to that study, however, our study demonstrated a relatively large improvement in the number of inappropriate drugs from admission to discharge in both the control and intervention groups. The large improvement seen in the control group could be the result of an effect of the discharge medication reconciliation process on medication appropriateness, since this activity was implemented in both groups.
In conclusion, the results of this study indicate that medication reconciliation and review, according to the integrated medicines management model demonstrated here, can reduce the number of inappropriate drugs taken by elderly patients during a hospital stay and the number of subsequent unscheduled drug-related hospital visits.
